# A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)

> **NCT07593144** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Foresight Therapeutics (Hefei) Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** FS-207

## Key facts

- **NCT ID:** NCT07593144
- **Lead sponsor:** Foresight Therapeutics (Hefei) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2029-01-15
- **Final completion:** 2029-05-15
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593144, "A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT07593144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*